Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients

about

Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients

Item

http://www.wikidata.org/entity/Q57913577

description

im August 2014 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 18 August 2014

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2014

@uk

name

Characteristics associated wit ...... in multiple sclerosis patients

@en

Characteristics associated wit ...... in multiple sclerosis patients

@nl

type

Item

label

Characteristics associated wit ...... in multiple sclerosis patients

@en

Characteristics associated wit ...... in multiple sclerosis patients

@nl

prefLabel

Characteristics associated wit ...... in multiple sclerosis patients

@en

Characteristics associated wit ...... in multiple sclerosis patients

@nl

P1476

Characteristics associated wit ...... in multiple sclerosis patients

@en

P2093

Eric M Yoshida

http://www.w3.org/2001/XMLSchema#string

Marcelo Kremenchutzky

http://www.w3.org/2001/XMLSchema#string

Trudy L Campbell

http://www.w3.org/2001/XMLSchema#string

P2860

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.

A method for estimating the probability of adverse drug reactions

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.

Mechanisms of drug-induced liver injury: from bedside to bench.

Outcome and prognostic markers in severe drug-induced liver disease.

Drug-related hepatotoxicity.

Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.

P304

1305-1317

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2014.947958

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25134421

http://www.w3.org/2001/XMLSchema#string